The Center for Biologics Evaluation and Research (CBER) may issue several types of regulatory action letters. These letters are ordinarily issued to biological product manufacturers in the effort to stop practices found to be in violation of the regulations and to promote corrective action.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/VFsGtAP
No comments:
Post a Comment